Small-cap Virpax (VRPX) Up 100% Today to Push Weekly Gains to Over 500% After Receiving FDA Guidance on SARS and Flu Treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Virpax Pharmaceuticals (VRPX) halted on LUDP
August 18, 2021 9:40 AM EDTVirpax Pharmaceuticals (NASDAQ: VRPX) halted on LUDP
... MoreVirpax Pharmaceuticals (VRPX) Extends Gain, Now Up 140%
August 18, 2021 7:27 AM EDTVirpax Pharmaceuticals (NASDAQ: VRPX) Extends Gain, Now Up 140%
Virpax Pharmaceuticals (VRPX) Extends Yesterday's Gain, Up Another 65%
August 18, 2021 6:07 AM EDTVirpax Pharmaceuticals (NASDAQ: VRPX) Extends Yesterday's Gain, Up Another 65%
Shares were Up 265% Yesterday... More
Virpax Pharmaceuticals (VRPX) Receives FDA Response and Guidance on MMS019
August 17, 2021 9:01 AM EDTVirpax® Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has received a written pre-investigational new drug (pre-IND) response from the U.S. Food and Drug Administration (FDA) for MMS019, its patented and proprietary high-density molecular masking spray under development for use as an anti-viral barrier product. Virpax believes the results of the pre-IND response support further research on MMS019 as an intranasal protective... More
